By Colin Kellaher

Amgen has hired James Bradner as executive vice president of research and development and chief scientific officer of the biotechnology company.

Amgen on Thursday said Bradner has been a clinician at the Dana-Farber Cancer Institute for the past year after a stint as president of the Novartis Institutes for BioMedical Research, where he was a member of the executive committee of Swiss drugmaker Novartis.

Amgen said Bradner succeeds David Reese, who is taking on the newly created post of executive vice president and chief technology officer, and will be responsible for accelerating the use of technology and artificial intelligence across all facets of the Thousand Oaks, Calif., company.

Bradner, meanwhile, will be responsible for advancing Amgen's pipeline and its worldwide research efforts.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 14, 2023 09:38 ET (14:38 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024 Click Here for more Amgen Charts.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024 Click Here for more Amgen Charts.